Literature DB >> 26055245

Inflammasome activation and function in liver disease.

Gyongyi Szabo1, Jan Petrasek1.   

Abstract

Inflammation contributes to the pathogenesis of most acute and chronic liver diseases. Inflammasomes are multiprotein complexes that can sense danger signals from damaged cells and pathogens and assemble to mediate caspase-1 activation, which proteolytically activates the cytokines IL-1β and IL-18. In contrast to other inflammatory responses, inflammasome activation uniquely requires two signals to induce inflammation, therefore setting an increased threshold. IL-1β, generated upon caspase-1 activation, provides positive feed-forward stimulation for inflammatory cytokines, thereby amplifying inflammation. Inflammasome activation has been studied in different human and experimental liver diseases and has been identified as a major contributor to hepatocyte damage, immune cell activation and amplification of liver inflammation. In this Review, we discuss the different types of inflammasomes, their activation and biological functions in the context of liver injury and disease progression. Specifically, we focus on the triggers of inflammasome activation in alcoholic steatohepatitis and NASH, chronic HCV infection, ischaemia-reperfusion injury and paracetamol-induced liver injury. The application and translation of these discoveries into therapies promises novel approaches in the treatment of inflammation in liver disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26055245     DOI: 10.1038/nrgastro.2015.94

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  196 in total

Review 1.  Alcoholic liver disease.

Authors:  Robert S O'Shea; Srinivasan Dasarathy; Arthur J McCullough
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

Review 2.  Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes.

Authors:  Nathalie Esser; Sylvie Legrand-Poels; Jacques Piette; André J Scheen; Nicolas Paquot
Journal:  Diabetes Res Clin Pract       Date:  2014-04-13       Impact factor: 5.602

Review 3.  Interleukin-18, a proinflammatory cytokine.

Authors:  C A Dinarello
Journal:  Eur Cytokine Netw       Date:  2000-09       Impact factor: 2.737

4.  Converting enzyme-independent release of tumor necrosis factor alpha and IL-1beta from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3.

Authors:  C Coeshott; C Ohnemus; A Pilyavskaya; S Ross; M Wieczorek; H Kroona; A H Leimer; J Cheronis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

Review 5.  Gut-liver axis in alcoholic liver disease.

Authors:  Gyongyi Szabo
Journal:  Gastroenterology       Date:  2014-11-11       Impact factor: 22.682

6.  Hepatitis C virus activates interleukin-1β via caspase-1-inflammasome complex.

Authors:  Dylan Burdette; Adam Haskett; Lance Presser; Steven McRae; Jawed Iqbal; Gulam Waris
Journal:  J Gen Virol       Date:  2011-10-12       Impact factor: 3.891

7.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

Review 8.  Signalling pathways in alcohol-induced liver inflammation.

Authors:  Pranoti Mandrekar; Gyongyi Szabo
Journal:  J Hepatol       Date:  2009-03-28       Impact factor: 25.083

9.  Interleukin-1 participates in the progression from liver injury to fibrosis.

Authors:  Roben G Gieling; Karen Wallace; Yuan-Ping Han
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-04-02       Impact factor: 4.052

Review 10.  Innate immune cell networking in hepatitis C virus infection.

Authors:  Banishree Saha; Gyongyi Szabo
Journal:  J Leukoc Biol       Date:  2014-07-07       Impact factor: 4.962

View more
  189 in total

1.  S-allylmercaptocysteine improves nonalcoholic steatohepatitis by enhancing AHR/NRF2-mediated drug metabolising enzymes and reducing NF-κB/IκBα and NLRP3/6-mediated inflammation.

Authors:  Qian Yu; Yann-Yin Lee; Zheng-Yun Xia; Emily C Liong; Jia Xiao; George L Tipoe
Journal:  Eur J Nutr       Date:  2020-06-17       Impact factor: 5.614

2.  Lipopolysaccharide downregulates macrophage-derived IL-22 to modulate alcohol-induced hepatocyte cell death.

Authors:  Yaming Liu; Vikas K Verma; Harmeet Malhi; Greg J Gores; Patrick S Kamath; Arun Sanyal; Naga Chalasani; Bin Gao; Vijay H Shah
Journal:  Am J Physiol Cell Physiol       Date:  2017-06-21       Impact factor: 4.249

3.  Effect of Gevokizumab on Interleukin-1β-Mediated Cytochrome P450 3A4 and Drug Transporter Repression in Cultured Human Hepatocytes.

Authors:  Amélie Moreau; Marc Le Vée; Elodie Jouan; Claire Denizot; Yannick Parmentier; Olivier Fardel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

4.  Effects of NLRP6 in Cerebral Ischemia/Reperfusion (I/R) Injury in Rats.

Authors:  Changchang Meng; Jinyan Zhang; Luyu Zhang; Yueting Wang; Zhenyu Li; Jing Zhao
Journal:  J Mol Neurosci       Date:  2019-07-02       Impact factor: 3.444

5.  Editor's Highlight: An Impaired Immune Tolerance Animal Model Distinguishes the Potential of Troglitazone/Pioglitazone and Tolcapone/Entacapone to Cause IDILI.

Authors:  Alastair Mak; Ryuji Kato; Kyle Weston; Anthony Hayes; Jack Uetrecht
Journal:  Toxicol Sci       Date:  2018-02-01       Impact factor: 4.849

6.  Design and rationale of a multicenter defeat alcoholic steatohepatitis trial: (DASH) randomized clinical trial to treat alcohol-associated hepatitis.

Authors:  Srinivasan Dasarathy; Mack C Mitchell; Bruce Barton; Craig J McClain; Gyongyi Szabo; Laura E Nagy; Svetlana Radaeva; Arthur J McCullough
Journal:  Contemp Clin Trials       Date:  2020-07-31       Impact factor: 2.226

7.  Inflammasome-mediated inflammation and fibrosis: It is more than just the IL-1β.

Authors:  Muhammad Amir; Mark J Czaja
Journal:  Hepatology       Date:  2017-12-23       Impact factor: 17.425

Review 8.  Lytic cell death in metabolic liver disease.

Authors:  Jérémie Gautheron; Gregory J Gores; Cecília M P Rodrigues
Journal:  J Hepatol       Date:  2020-04-13       Impact factor: 25.083

Review 9.  Grand Rounds: Alcoholic Hepatitis.

Authors:  Ashwani K Singal; Alexandre Louvet; Vijay H Shah; Patrick S Kamath
Journal:  J Hepatol       Date:  2018-06-13       Impact factor: 25.083

10.  Understanding Disseminated Intravascular Coagulation and Hepatobiliary Dysfunction Multiple Organ Failure in Hyperferritinemic Critical Illness.

Authors:  Joseph A Carcillo; Bita Shakoory; Dennis Simon; Kate Kernan
Journal:  Pediatr Crit Care Med       Date:  2018-10       Impact factor: 3.624

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.